|本期目录/Table of Contents|

[1]高凤华,王先火综述,张会来审校.滤泡性淋巴瘤联合用药现状与进展[J].天津医科大学学报,2023,29(02):212-217.
点击复制

滤泡性淋巴瘤联合用药现状与进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
29卷
期数:
2023年02期
页码:
212-217
栏目:
综述
出版日期:
2023-03-20

文章信息/Info

Title:
-
文章编号:
1006-8147（2023）02-0212-06
作者:
高凤华; 王先火综述; 张会来审校
天津医科大学肿瘤医院淋巴瘤科，中美淋巴瘤血液诊治中心
Author(s):
-
关键词:
滤泡性淋巴瘤; 联合治疗; 无化疗方案; 靶向治疗药物
Keywords:
-
分类号:
R733.4
DOI:
-
文献标志码:
A
摘要:
滤泡性淋巴瘤（FL）是最常见的惰性非霍奇金淋巴瘤。过去20年的治疗进展改善了FL预后，其中R-CHOP是最常用的联合治疗方案，无化疗的R2（利妥昔单抗+来那度胺）方案也备受关注。近年来，磷脂酰肌醇3-激酶抑制剂、蛋白酶体抑制剂、Bcl-2抑制剂、BTK抑制剂、EZH2抑制剂和CAR-T等靶向治疗和免疫治疗药物发展迅速，也为滤泡性淋巴瘤患者带来新的曙光。本综述将分别介绍滤泡性淋巴瘤治疗中联合用药现状和靶向/免疫治疗联合方案的研究进展。
Abstract:
-

参考文献/References:

[1] CARBONE A，ROULLAND S，GLOGHINI A，et al. Follicular lym－phoma[J]. Nat Rev Dis Primers，2019，5（1）：83.
[2] FREEDMAN A，JACOBSEN E. Follicular lymphoma：2020 update on diagnosis and management[J]. Am J Hematol，2020，95（3）：316-327.
[3] DREYLING M，GHIELMINI M，RULE S，et al. Newly diagnosed and relapsed follicular lymphoma：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up[J]. Ann Oncol，2021，32（3）：298-308.
[4] 黄慧强.中国滤泡性淋巴瘤诊断与治疗指南（2020年版）[J].中华血液学杂志，2020，41（7）：537-544.
[5] ARDESHNA K M，QIAN W，SMITH P，et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage，asymp－tomatic，non-bulky follicular lymphoma：an open-label randomised phase 3 trial [J]. Lancet Oncol，2014，15（4）：424-435.
[6] MARCUS R，DAVIES A，ANDO K，et al. Obinutuzumab for the first-line treatment of follicular lymphoma[J]. N Engl J Med，2017， 377（14）：1331-1344.
[7] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）淋巴瘤诊疗指南2021 [M].北京：人民卫生出版社，2021.
[8] HIDDEMANN W，KNEBA M，DREYLING M，et al. Frontline thera－py with rituximab added to the combination of cyclophosphamide， doxorubicin，vincristine，and prednisone（CHOP）significantly im－proves the outcome for patients with advanced-stage follicular lym－phoma compared with therapy with CHOP alone：results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J]. Blood，2005，106（12）：3725-3732.
[9] MARCUS R，IMRIE K，BELCH A，et al. CVP chemotherapy plus rit－uximab compared with CVP as first-line treatment for advanced fol－licular lymphoma [J]. Blood，2005，105（4）：1417-1423.
[10] LINSCHOTEN M，KAMPHUIS J A M，VAN RHENEN A，et al. Car－diovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide，doxorubicin，vincristine， and prednisone（CHOP）or CHOP with rituximab（R-CHOP）：a sys－tematic review and meta-analysis[J]. Lancet Haematol，2020，7（4）：e295-e308.
[11] MUNAKATA W，TOBINAI K. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma[J]. Expert Opin Drug Discov，2016，11（11）：1123-1130.
[12] RUMMEL M J，NIEDERLE N，MASCHMEYER G，et al. Bendamus－tine plus rituximab versus CHOP plus rituximab as first-line treat－ment for patients with indolent and mantle-cell lymphomas：an open-label，multicentre，randomised，phase 3 non-inferiority trial[J]. Lancet，2013，381（9873）：1203-1210.
[13] CHESON B D，CHUA N，MAYER J，et al. Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN study[J]. J Clin On－col，2018，36（22）：2259-2266.
[14] BACHY E，SALLES G. Are we nearing an era of chemotherapy-free management of indolent lymphoma ? [J]. Clin Cancer Res，2014， 20（20）：5226-5239.
[15] GARCIAZ S，COSO D，SCHIANO DE COLELLA J M，et al. Lenalido－mide for the treatment of B-cell lymphoma[J]. Expert Opin Investig Drugs，2016，25（9）：1103-1116.
[16] HANEL W，EPPERLA N. Evolving therapeutic landscape in follicu－lar lymphoma：a look at emerging and investigational therapies[J]. J Hematol Oncol，2021，14（1）：104.
[17] MENARD C，ROSSILLE D，DULONG J，et al. Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lym－phoma[J]. Blood Adv，2021，5（8）：2063-2074.
[18] WANG N，QIN W，ZHENG Z，et al. Hepatitis B virus-associated fol－licular lymphoma presents T-cell inflamed phenotype and response to lenalidomide[J]. Cancer Commun（Lond），2022，42（2）：170-174.
[19] MORSCHHAUSER F，FOWLER N H，FEUGIER P，et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma[J]. N Engl J Med，2018，379（10）：934-947.
[20] LEONARD J P，TRNENY M，IZUTSU K，et al. AUGMENT：A PhaseⅢStudy of lenalidomide plus rituximab versus placebo plus ritux－imab in relapsed or refractory indolent lymphoma[J]. J Clin Oncol， 2019，37（14）：1188-1199.
[21] MORSCHHAUSER F，SALLES G，LE GOUILL S，et al. An open-la－bel phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma [J]. Blood，2018，132（14）：1486-1494.
[22] BACHY E，HOUOT R，FEUGIER P，et al. Obinutuzumab plus lenalidomide（GALEN）in advanced，previously untreated follicular lymphoma in need of systemic therapy[J]. Blood，2022，139（15）：2338-2346.
[23] DIEFENBACH C，KAHL B S，MCMILLAN A，et al. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with re－lapsed or refractory follicular lymphoma：a cohort of a multicentre， single-arm，phase 1b/2 study[J].Lancet Haematol，2021，8（12）：e891-e901.
[24] OKKENHAUG K，VANHAESEBROECK B. PI3K in lymphocyte de－velopment，differentiation and activation[J]. Nat Rev Immunol，2003， 3（4）：317-330.
[25] EFREMOV D G，TURKALJ S，LAURENTI L. Mechanisms of B cell receptor activation and responses to b cell receptor inhibitors in b cell malignancies[J]. Cancers（Basel），2020，12（6）：1396.
[26] SAPON-COUSINEAU V，SAPON-COUSINEAU S，ASSOULINE S. PI3K inhibitors and their role as novel agents for targeted therapy in lymphoma[J]. Curr Treat Options Oncol，2020，21（6）：51.
[27] DREYLING M，SANTORO A，MOLLICA L，et al. Phosphatidylinos－itol 3-kinase inhibition by copanlisib in relapsed or refractory indo－lent lymphoma[J]. J Clin Oncol，2017，35（35）：3898-3905.
[28] DREYLING M，SANTORO A，MOLLICA L，et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with re－lapsed or refractory indolent lymphoma：2-year follow-up of the CHRONOS-1 study[J]. Am J Hematol，2020，95（4）：362-371.
[29] MATASAR M J，CAPRA M，魻ZCAN M，et al. Copanlisib plus ritux－imab versus placebo plus rituximab in patients with relapsed indo－lent non-Hodgkin lymphoma（CHRONOS-3）：a double-blind，ran－domised，placebo-controlled，phase 3 trial[J]. Lancet Oncol，2021， 22（5）：678-689.
[30] MANASANCH E E，ORLOWSKI R Z. Proteasome inhibitors in can－cer therapy [J]. Nat Rev Clin Oncol，2017，14（7）：417-433.
[31] ASSOULINE S E，CHANG J，CHESON B D，et al. Phase 1 dose-es－calation study of Ⅳ ixazomib，an investigational proteasome in－hibitor，in patients with relapsed/refractory lymphoma[J]. Blood Can－cer J，2014，4（10）：e251.
[32] EVENS A M，SMITH M R，LOSSOS I S，et al. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma：a multicentre phase Ⅱstudy[J]. Br J Haematol，2014，166（4）：514-520.
[33] BAIOCCHI R A，ALINARI L，LUSTBERG M E，et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma[J]. Cancer，2011，117（11）：2442-2451.
[34] COIFFIER B，OSMANOV E A，HONG X，et al. Bortezomib plus rit－uximab versus rituximab alone in patients with relapsed，rituximab-naive or rituximab -sensitive，follicular lymphoma：a randomised phase 3 trial [J].Lancet Oncol，2011，12（8）：773-784.
[35] NASTOUPIL L J，WESTIN J R，FOWLER N H，et al. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma：interim results of an on open-label， phaseⅡstudy[J]. J Clin Oncol，2017，35（15 suppl）：7519.
[36] HAWKES E A，LEE S T，CHONG G，et al. Immune priming with nivolumab followed by nivolumab and rituximab in first-line treat－ment of follicular lymphoma：the phase 2 1st FLOR study[J]. J Clin Oncol，2021，39（15_suppl）：7560.
[37] MORSCHHAUSER F，GHOSH N，LOSSOS I S，et al. Obinutuzum－ab-atezolizumab-lenalidomide for the treatment of patients with re－lapsed/refractory follicular lymphoma：final analysis of a phase Ib/II trial[J]. Blood Cancer J，2021，11（8）：147.
[38] DEEKS E D. Polatuzumab vedotin：first global approval[J]. Drugs， 2019，79（13）：1467-1475.
[39] MORSCHHAUSER F，FLINN I W，ADVANI R，et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with re－lapsed or refractory non-Hodgkin lymphoma：final results from a phase 2 randomised study（ROMULUS）[J]. Lancet Haematol，2019， 6（5）：e254-e265.
[40] ASHKENAZI A，FAIRBROTHER W J，LEVERSON J D，et al. From basic apoptosis discoveries to advanced selective BCL-2 family in－hibitors[J]. Nat Rev Drug Discov，2017，16（4）：273-284.
[41] DE VOS S，SWINNEN L J，WANG D，et al. Venetoclax，bendamus－tine，and rituximab in patients with relapsed or refractory NHL：a phase Ib dose-finding study[J]. Ann Oncol，2018，29（9）：1932-1938.
[42] ZINZANI P L，FLINN I W，YUEN S L S，et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in re－lapsed/refractory follicular lymphoma [J]. Blood，2020，136（23）：2628-2637.
[43] HONIGBERG L A，SMITH A M，SIRISAWAD M，et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignan－cy[J]. Proc Natl Acad Sci U S A，2010，107（29）：13075-13080.
[44] FOWLER N H，NASTOUPIL L，DE VOS S，et al. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma[J]. Br J Haematol，2020，189（4）：650-660.
[45] MADDOCKS K，CHRISTIAN B，JAGLOWSKI S，et al. A phase 1/1b study of rituximab，bendamustine，and ibrutinib in patients with un－treated and relapsed/refractory non-Hodgkin lymphoma[J]. Blood， 2015，125（2）：242-248.
[46] DUAN R，DU W，GUO W. EZH2：a novel target for cancer treat－ment [J]. J Hematol Oncol，2020，13（1）：104.
[47] CAHILL K E，SMITH S M. Follicular lymphoma：a focus on current and emerging therapies[J]. Oncology （Williston Park），2022，36（2）：97-106.
[48] VON KEUDELL G，SALLES G. The role of tazemetostat in relapsed/refractory follicular lymphoma [J]. Ther Adv Hematol，2021，12：20406207211015882.
[49] SARKOZY C，MORSCHHAUSER F，DUBOIS S，et al. A LYSA Phase Ib Study of Tazemetostat（EPZ-6438）plus R-CHOP in Pa－tients with Newly Diagnosed Diffuse Large B-Cell Lymphoma（DL－BCL）with poor prognosis features[J]. Clin Cancer Res，2020，26（13）：3145-3153.
[50] DAVILA M L，BOUHASSIRA D C，PARK J H，et al. Chimeric anti－gen receptors for the adoptive T cell therapy of hematologic malig－nancies[J]. Int J Hematol，2014，99（4）：361-371.
[51] KOCHENDERFER J N，WILSON W H，JANIK J E，et al. Eradica－tion of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19[J]. Blood，2010，116（20）：4099-4102.
[52] WANG J，DENG Q，JIANG Y Y，et al. CAR-T 19 combined with re－duced-dose PD-1 blockade therapy for treatment of refractory follic－ular lymphoma：a case report [J]. Oncol Lett，2019，18 （5）：4415-4420.
[53] LIU M，DENG H，MU J，et al. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma[J]. Cancer Sci，2021，112（7）：2642-2651.

相似文献/References:

备注/Memo

备注/Memo:
基金项目： 国家自然科学基金（81770213）；天津市自然科学基金（19JCYBJC26500）
作者简介：高凤华（1993-），女，博士在读，研究方向：淋巴瘤的基础与临床研究；
通信作者：张会来，E-mail：zhlwgq@126.com。
更新日期/Last Update: 2023-04-30